Compare MBBC & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBBC | EDSA |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 51.5M |
| IPO Year | 2020 | 2018 |
| Metric | MBBC | EDSA |
|---|---|---|
| Price | $15.23 | $4.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 2.0K | ★ 75.8K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 122.22 | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.25 | $0.72 |
| 52 Week High | $15.79 | $20.32 |
| Indicator | MBBC | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 57.44 | 44.04 |
| Support Level | $14.63 | $4.80 |
| Resistance Level | $15.77 | $6.62 |
| Average True Range (ATR) | 0.12 | 0.61 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 93.94 | 30.98 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.